We serve Chemical Name:methyl 3-amino-5-bromo-2-fluorobenzoate CAS:1339049-19-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:methyl 3-amino-5-bromo-2-fluorobenzoate
CAS.NO:1339049-19-2
Synonyms:methyl 3-amino-5-bromo-2-fluorobenzoate
Molecular Formula:C8H7BrFNO2
Molecular Weight:248.04900
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:52.32000
Exact Mass:246.96400
LogP:2.53820
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like methyl 3-amino-5-bromo-2-fluorobenzoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl 3-amino-5-bromo-2-fluorobenzoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methyl 3-amino-5-bromo-2-fluorobenzoate Use and application,methyl 3-amino-5-bromo-2-fluorobenzoate technical grade,usp/ep/jp grade.
Related News: Bluebird also earned an approval Wednesday in Europe for its gene therapy Lenti-D for children with early cerebral adrenoleukodystrophy and an ABCD1 genetic mutation without a matched sibling donor. 3-(2-trimethylsilylethynyl)benzaldehyde manufacturers Italian medical packaging firm Stevanato Group went public on the Big Board on July 16, raising $672 million and helping push up the fortune of the billionaire Stevanato family behind the company. 1-(2H33)Hexadecanol suppliers But when it came to deciding on whether Americans with compromised immune systems should get an extra dose of any COVID-19 vaccine, the CDC said it would need to wait for the FDA to give its regulatory thumbs up first. That could come either through amending its emergency use nods or awarding full approvals. ethaverine hydrochloride vendor & factory Bluebird also earned an approval Wednesday in Europe for its gene therapy Lenti-D for children with early cerebral adrenoleukodystrophy and an ABCD1 genetic mutation without a matched sibling donor.,The expansion will include six 1,000L small molecule reactors, four 1,500L vessels, and isolation equipment providing mid-scale capacity to bridge between early-phase and late-phase production.
